Who
Charles Elliott Sigal
Director
Company insider
Files Form 4 as: Director, Vir Biotechnology; Director, Alnylam Pharmaceuticals; Director, Surface Oncology; Director, Adaptimmune Therapeutics.
In numbers
- Trades disclosed
- 52
- Buys
- 8
- Sells
- 0
- Bought
- $338K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 16 May 2016
- Last trade
- 27 May 2026
- Last filed
- 28 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 28 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 27 May 2026filed 28 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,441 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —671 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,558 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —775 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 16 May 2024filed 20 May 2024 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,228 at $0.00 | filing |
| 8 Sep 2023filed 8 Sep 2023 | Surface Oncologyoption or derivative | SEC FORM 4 Code D | —113,636 at $0.00 | filing |
| 8 Sep 2023filed 8 Sep 2023 | Surface Oncology | SEC FORM 4 Code D | —45,453 | filing |
| 3 Jul 2023filed 3 Jul 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —933,317 at $0.00 | filing |
| 22 May 2023filed 24 May 2023 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,054 at $0.00 | filing |
| 22 May 2023filed 24 May 2023 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —6,027 at $0.00 | filing |
News
Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month High – Here's What HappenedVIR · tickerreport.com · 12 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastVIR · dailypolitical.com · 11 Oct 2026Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $22.00VIR · tickerreport.com · 10 Oct 2026
0 headlines in the last 90 days name Charles Elliott Sigal; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.